Form 4: Pfizer CEO Albert Bourla Acquires Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, acquired 79 phantom stock units valued at $25.58 each, increasing his beneficial ownership to 743,136 units.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 79 phantom stock units.
• The acquisition occurred on January 14, 2026.
• Each unit represents one phantom share of common stock and was acquired at a price of $25.58 per unit.
• These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Following this transaction, Bourla beneficially owns 743,136 phantom stock units.
• The units are settled in cash upon separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock units by the CEO, while part of a deferred compensation plan, indicates continued alignment of management's interests with the company's performance and shareholder value. It's a routine, non-market transaction but still an increase in beneficial ownership.

Positives

• Acquisition of phantom stock units by the CEO indicates continued alignment of management's interests with shareholder value.
• Participation in the Nonfunded Deferred Compensation and Supplemental Savings Plan suggests a long-term commitment to the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Acquisition of 79 phantom stock units by CEO Albert Bourla under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Stakeholder Impact

• Shareholders: The increase in beneficial ownership by the CEO, even through a deferred compensation plan, can be viewed positively as it aligns management's interests with shareholder value.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units by Pfizer's CEO as part of a deferred compensation plan. While it indicates continued alignment of management's interests with the company, it does not represent a direct market purchase or provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions.

Keywords

Pfizer, PFE, Albert Bourla, Insider Trading, Form 4, Phantom Stock, Executive Compensation, Deferred Compensation, Stock Units